Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia. Show more

4960 Peachtree Industrial Boulevard, Norcross, GA, 30071, United States

Biotechnology

Healthcare

Market Cap

150.7M

52 Wk Range

$1.21 - $7.13

Previous Close

$2.29

Open

$2.31

Volume

320,108

Day Range

$2.19 - $2.38

Enterprise Value

267.3M

Cash

17.72M

Avg Qtr Burn

-6.042M

Insider Ownership

29.10%

Institutional Own.

17.93%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Belapectin (GR-MD-02) Details Non-alcoholic steatohepatitis , metabolic dysfunction-associated steatohepatitis	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Belapectin (GR-MD-02) + keytruda Details Head and neck cancer, Head and neck squamous cell carcinoma	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Belapectin (GR-MD-02) Details Psoriasis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.